Richard A Rudick

Richard A Rudick

UNVERIFIED PROFILE

Are you Richard A Rudick?   Register this Author

Register author
Richard A Rudick

Richard A Rudick

Publications by authors named "Richard A Rudick"

Are you Richard A Rudick?   Register this Author

88Publications

676Reads

36Profile Views

Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study.

Lancet Neurol 2018 10 22;17(10):870-884. Epub 2018 Aug 22.

Medicine Institute, Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(18)30245-XDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197820PMC
October 2018

Experience with fingolimod in clinical practice.

Int J Neurosci 2015 29;125(9):678-85. Epub 2014 Oct 29.

1Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/00207454.2014.969839DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414718PMC
May 2016

The Future of Research in Multiple Sclerosis.

JAMA Neurol 2015 Aug;72(8):853-4

Biogen, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaneurol.2015.0270DOI Listing
August 2015

The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis.

JAMA Neurol 2014 Nov;71(11):1386-93

Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio7currently with Biogen Idec, Weston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaneurol.2014.1895DOI Listing
November 2014

Defining the clinical course of multiple sclerosis: the 2013 revisions.

Neurology 2014 Jul 28;83(3):278-86. Epub 2014 May 28.

From the Corinne Goldsmith Dickenson Center for Multiple Sclerosis (F.D.L., A.E.M.), Icahn School of Medicine at Mount Sinai, New York, NY; Scientific and Clinical Review Associates, LLC (S.C.R.), Salisbury, CT; The Mellen Center for MS Treatment and Research (J.A.C., R.J.F., R.A.R.), Cleveland Clinic, OH; the Department of Biostatistics (G.R.C.), University of Alabama at Birmingham; the Danish Multiple Sclerosis Center (P.S.S.), Department of Neurology, Copenhagen University Hospital Rigshospitalet, Denmark; University College London Institute of Neurology (A.J.T.), UK; the Department of Neurology (J.S.W., J.A.L.), University of Texas Health Sciences Center, Houston; the Department of Neurology (L.J.B.), New York University Langone Medical Center, New York; the Division of Neurology (B. Banwell), The Children's Hospital of Philadelphia, PA; the Departments of Radiology and Nuclear Medicine (F.B.) and Neurology (C.H.P.), VU Medical Center, Amsterdam, the Netherlands; Research Programs Department (B. Bebo), National Multiple Sclerosis Society, New York, NY; the Department of Neurology (P.A.C.), The Johns Hopkins Hospital, Baltimore, MD; Fédération de Neurologie (M.C.), CHU Hôpital Purpan, Toulouse, France; the Department of Neurology (G.C.), Scientific Institute San Raffaele, University Vita-Salute San Raffaele, Milan, Italy; University of Ottawa and the Ottawa Hospital Research Institute (M.S.F.), Canada; the Department of Neurology (A.D.G.), University of Rochester Medical Center, NY; the Departments of Neurology, Radiology and Neuroscience (M.I.), Mount Sinai School of Medicine, New York, NY; the Department of Neurology (L.K.), University Hospital, Basel, Switzerland; the Department of Neurology (B.C.K.), Heinrich-Heine-University, Düsseldorf, Germany; the Department of Neurology (C.L.), Salpêtrière Hospital, UPMC, Paris, France; the Department of Neurology-Neuroimmunology (X.M.), Cemcat, Hospital Universitari Vall d'Hebron, Barcelona, Spain; the Division of

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000000560DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117366PMC
July 2014

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.

Neurology 2014 Jul 4;83(1):78-86. Epub 2014 Jun 4.

From the Department of Neurology (P.O.), St. Michael's Hospital, Toronto, Canada; Department of Neurology (A.G.), University of Rochester, NY; Departments of Neurology and Biomedicine (L.K.), University Hospital Basel, Switzerland; Corinne Goldsmith Dickinson Center for MS at The Icahn School of Medicine at Mount Sinai (F.L.), New York, NY; Department of Neurology (C.P.), VU Medical Centre, Amsterdam, the Netherlands; Mellen Center for Multiple Sclerosis Treatment and Research (R.A.R.), Cleveland Clinic Foundation, OH; Infusion Communications (K.H.), Haddam, CT; Departments of Safety and Benefit-Risk Management (L.M.C.) and Biostatistics (F.F.), Biogen Idec Inc., Cambridge; and Sarepta Therapeutics (P.D.), Cambridge, MA; P.D., a former employee of Biogen Idec Inc., was at the company during study conduct.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000000541DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114173PMC
July 2014

The Multiple Sclerosis Performance Test (MSPT): an iPad-based disability assessment tool.

J Vis Exp 2014 Jun 30(88):e51318. Epub 2014 Jun 30.

Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic Foundation.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3791/51318DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209820PMC
June 2014

Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan.

Mult Scler 2014 Jan 20;20(1):12-7. Epub 2013 Sep 20.

Mellen Center, Cleveland Clinic Foundation, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458513503392DOI Listing
January 2014

Assessing treatment response to interferon-β: is there a role for MRI?

Neurology 2014 Jan 11;82(3):248-54. Epub 2013 Dec 11.

From the Queen Mary University London (R.D., K.S., G.G.), Blizard Institute, UK; Neurological Institute (R.A.R.), Mellen Center for MS Treatment and Research, Cleveland, OH; and Royal London Hospital (R.D., B.T., K.S., G.G.), Barts Health NHS Trust, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000000036DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902760PMC
January 2014

MRI lesions: a surrogate for relapses in multiple sclerosis?

Lancet Neurol 2013 Jul 3;12(7):628-30. Epub 2013 Jun 3.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(13)70108-XDOI Listing
July 2013

Preventing brain atrophy should be the gold standard of effective therapy in MS (after the first year of treatment): Yes.

Mult Scler 2013 Jul;19(8):1003-4

Mellen Center for MS Treatment and Research, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458513482385DOI Listing
July 2013

Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic.

JAMA Neurol 2013 Mar;70(3):338-44

Cleveland Clinic Mellen Center for Multiple Sclerosis Treatment and Research, 9500 Euclid Ave, Cleveland, OH 44195-5244, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/2013.jamaneurol.211DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3792494PMC
March 2013

Author response.

Neurology 2013 Feb;80(8):777

View Article

Download full-text PDF

Source
February 2013

Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.

Ann Neurol 2013 Jan;73(1):95-103

Neurological Institute, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.23758DOI Listing
January 2013

Early tolerability and safety of fingolimod in clinical practice.

J Neurol Sci 2012 Dec 3;323(1-2):167-72. Epub 2012 Oct 3.

Mellen Center, Department of Neurology, Cleveland Clinic, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2012.09.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970706PMC
December 2012

Measurement and clinical effect of grey matter pathology in multiple sclerosis.

Lancet Neurol 2012 Dec;11(12):1082-92

Department of Anatomy and Neurosciences, Section of Clinical Neuroscience, VU University Medical Center, Amsterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(12)70230-2DOI Listing
December 2012

Time to integrate clinical and research informatics.

Sci Transl Med 2012 Nov;4(162):162fs41

Neurological Institute Center for Outcomes Research and Evaluation, Cleveland Clinic, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://stm.sciencemag.org/cgi/doi/10.1126/scitranslmed.30045
Publisher Site
http://dx.doi.org/10.1126/scitranslmed.3004583DOI Listing
November 2012

The elusive biomarker for personalized medicine in multiple sclerosis: the search continues.

Authors:
Richard A Rudick

Neurology 2012 Aug 9;79(6):498-9. Epub 2012 May 9.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0b013e318259e13aDOI Listing
August 2012

Multiple sclerosis or multiple possibilities: the continuing problem of misdiagnosis.

Neurology 2012 Jun 11;78(24):1904-6. Epub 2012 May 11.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0b013e318259e2e2DOI Listing
June 2012

MS clinical trials: what can subgroup analyses teach us?

Authors:
Richard A Rudick

Lancet Neurol 2012 May 10;11(5):386-8. Epub 2012 Apr 10.

Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(12)70066-2DOI Listing
May 2012

Risk stratification and patient counseling for natalizumab in multiple sclerosis.

Neurology 2012 Feb 25;78(6):436-7. Epub 2012 Jan 25.

Department of Neurology and Neurological Institute, ClevelandClinic, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://www.neurology.org/cgi/doi/10.1212/WNL.0b013e318245d2d
Publisher Site
http://dx.doi.org/10.1212/WNL.0b013e318245d2d0DOI Listing
February 2012

The role of cell type-specific responses in IFN-β therapy of multiple sclerosis.

Proc Natl Acad Sci U S A 2011 Dec 21;108(49):19689-94. Epub 2011 Nov 21.

Department of Molecular Genetics, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1117347108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241780PMC
December 2011

Oral treatment for multiple sclerosis.

Lancet Neurol 2011 Nov;10(11):1026-34

Department of Neurology, Multiple Sclerosis Centre Amsterdam, Vrije University Medical Centre, Amsterdam, Netherlands.

View Article

Download full-text PDF

Source
http://www.thelancet.com/pdfs/journals/laneur/PIIS1474-4422(
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S147444221170228
Publisher Site
http://dx.doi.org/10.1016/S1474-4422(11)70228-9DOI Listing
November 2011

Multiple sclerosis, natalizumab, and PML: helping patients decide.

Authors:
Richard A Rudick

Cleve Clin J Med 2011 Nov;78 Suppl 2:S18-23

Mellen Center for Multiple Sclerosis, Cleveland Clinic, 9500 Euclid Ave., U10, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3949/ccjm.78.s2.05DOI Listing
November 2011

Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugs.

Curr Opin Neurol 2011 Jun;24(3):255-61

Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WCO.0b013e3283460542DOI Listing
June 2011

Beta-interferon for multiple sclerosis.

Exp Cell Res 2011 May 21;317(9):1301-11. Epub 2011 Mar 21.

Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexcr.2011.03.002DOI Listing
May 2011

Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up.

Arch Neurol 2010 Nov 12;67(11):1329-35. Epub 2010 Jul 12.

Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/archneurol.2010.150DOI Listing
November 2010

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.

Ann Neurol 2010 Sep;68(3):304-10

Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.22107DOI Listing
September 2010

Multiple sclerosis: is multiple sclerosis caused by venous insufficiency?

Authors:
Richard A Rudick

Nat Rev Neurol 2010 Sep;6(9):472-4

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrneurol.2010.117DOI Listing
September 2010

Validation of a self-report comorbidity questionnaire for multiple sclerosis.

Neuroepidemiology 2010 Aug 15;35(2):83-90. Epub 2010 Jun 15.

Department of Internal Medicine, University of Manitoba, Winnipeg, Man., Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000311013DOI Listing
August 2010

Measuring disability in relapsing-remitting MS.

Neurology 2010 Jul 30;75(4):296-7. Epub 2010 Jun 30.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0b013e3181ecf815DOI Listing
July 2010

Possible clinical outcome measures for clinical trials in patients with multiple sclerosis.

Ther Adv Neurol Disord 2010 Jul;3(4):229-39

University of Virginia, Department of Neurology, PO Box 800394, Charlottesville, VA 22908, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756285610374117DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002657PMC
July 2010

Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of life.

Neurology 2010 Apr;74 Suppl 3:S24-35

Mellen Center for Multiple Sclerosis Treatment and Research, U-10, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://www.neurology.org/cgi/doi/10.1212/WNL.0b013e3181dbb88
Publisher Site
http://dx.doi.org/10.1212/WNL.0b013e3181dbb884DOI Listing
April 2010

The multiple sclerosis functional composite: a clinically meaningful measure of disability.

Neurology 2010 Apr;74 Suppl 3:S8-15

Department of Neurology, VU Medical Centre, Free University Hospital, PO Box 7057, Amsterdam, 1007 MB, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0b013e3181dbb571DOI Listing
April 2010

Do interferon beta-1b and glatiramer acetate grow brain?

Lancet Neurol 2009 Dec;8(12):1085-6; author reply 1086-7

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(09)70312-6DOI Listing
December 2009

Heterogeneous, longitudinally stable molecular signatures in response to interferon-beta.

Ann N Y Acad Sci 2009 Dec;1182:58-68

Neuroinflammation Research Center, Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1749-6632.2009.05068.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2842953PMC
December 2009

Gray-matter injury in multiple sclerosis.

N Engl J Med 2009 Oct;361(15):1505-6

Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMcibr0905482DOI Listing
October 2009

A radical proposal: integrate clinical investigation into the U.S. health care system.

Sci Transl Med 2009 Oct;1(4):4cm4

Department of Neurology, Cleveland Clinic, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.3000296DOI Listing
October 2009

Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS.

J Neurol Sci 2009 Jul 19;282(1-2):106-11. Epub 2008 Dec 19.

Mellen Center for MS Treatment and Research U10, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2008.11.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726444PMC
July 2009

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis.

Lancet Neurol 2009 Jun;8(6):545-59

Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(09)70082-1DOI Listing
June 2009

Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment.

CNS Drugs 2008 ;22(10):827-39

Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/00023210-200822100-00004DOI Listing
January 2009

LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence.

Expert Opin Biol Ther 2008 Oct;8(10):1561-70

Mellen Center for Multiple Sclerosis Treatment and Research, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.8.10.1561 DOI Listing
October 2008

Gray matter atrophy in multiple sclerosis: a longitudinal study.

Ann Neurol 2008 Sep;64(3):255-65

Department of Biomedical Engineering, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ana.21436
Publisher Site
http://dx.doi.org/10.1002/ana.21436DOI Listing
September 2008

Natalizumab for the treatment of relapsing multiple sclerosis.

Biologics 2008 Jun;2(2):189-99

Cleveland Clinic Foundation, Cleveland, OH, USA;

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721353PMC
June 2008

Novel interferon-beta-induced gene expression in peripheral blood cells.

J Leukoc Biol 2007 Nov 20;82(5):1353-60. Epub 2007 Aug 20.

Neuroinflammation Research Center, Department of Neurosciences, Lerner Research Institute, NC30, Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1189/jlb.0507273DOI Listing
November 2007

Novel interferon-β-induced gene expression in peripheral blood cells.

J Leukoc Biol 2007 Nov;82(5):1353-1360

Neuroinflammation Research Center, Department of Neurosciences, Lerner Research Institute, Ohio, USA and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1189/jlb.0507273DOI Listing
November 2007

Interferon-beta treatment for multiple sclerosis.

Neurotherapeutics 2007 Oct;4(4):633-46

Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nurt.2007.07.001DOI Listing
October 2007

Imaging correlates of axonal swelling in chronic multiple sclerosis brains.

Ann Neurol 2007 Sep;62(3):219-28

Department of Biomedical Engineering, Lerner Research Institute, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.21113DOI Listing
September 2007

Developing a mentorship program for clinical researchers.

J Contin Educ Health Prof 2007 ;27(2):86-93

Department of Quantitative Health Sciences, Section on Health Outcomes Research and Clinical Epidemiology, and joint appointment, Department of Bioethics, Cleveland Clinic, Cleveland, Ohio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/chp.105DOI Listing
September 2007

Interferon-beta for multiple sclerosis: Long-term benefits?

Ann Neurol 2007 Apr;61(4):283-5

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.21119DOI Listing
April 2007

Chemokine receptors as biomarkers in multiple sclerosis.

Dis Markers 2006 ;22(4):227-33

Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, OH 44122, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850832PMC
http://dx.doi.org/10.1155/2006/694283DOI Listing
January 2007

Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study.

Ann Neurol 2006 Aug;60(2):236-42

Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.20883DOI Listing
August 2006

Disease modification in multiple sclerosis: issues with relevance to clinical trial designs in Alzheimer's disease.

Authors:
Richard A Rudick

Alzheimers Dement 2006 Jul;2(3):143-6

Mellen Center for Multiple Sclerosis, Department of Neurology, Cleveland Clinic Foundation, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jalz.2006.03.011DOI Listing
July 2006

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

N Engl J Med 2006 Mar;354(9):911-23

Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa044396DOI Listing
March 2006

Drug Insight: interferon treatment in multiple sclerosis.

Nat Clin Pract Neurol 2006 Jan;2(1):34-44

Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1038/ncpneuro0088
Publisher Site
http://dx.doi.org/10.1038/ncpneuro0088DOI Listing
January 2006

Should patients with relapsing multiple sclerosis be given a higher dose and frequency of interferon-beta1a?

Nat Clin Pract Neurol 2005 Nov;1(1):16-7

Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncpneuro0041DOI Listing
November 2005

Effects of sex hormones on costimulatory molecule expression in multiple sclerosis.

J Neuroimmunol 2005 Oct;167(1-2):190-203

Department of Neurosciences, NC30, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jneuroim.2005.06.014DOI Listing
October 2005

Primary progressive multiple sclerosis as a phenotype of a PLP1 gene mutation.

Ann Neurol 2005 Sep;58(3):470-3

Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.20601DOI Listing
September 2005

Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications.

Mult Scler 2005 Apr;11(2):140-5

Department of Neurology (Mellen Center), Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1191/1352458505ms1142oaDOI Listing
April 2005

Association of fatigue and brain atrophy in multiple sclerosis.

J Neurol Sci 2005 Feb 21;228(2):161-6. Epub 2004 Dec 21.

Department of Neurology (Mellen Center), The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2004.11.046DOI Listing
February 2005

Defining interferon beta response status in multiple sclerosis patients.

Ann Neurol 2004 Oct;56(4):548-55

Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.20224DOI Listing
October 2004

Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis.

Authors:
Richard A Rudick

J Neuroimaging 2004 Jul;14(3 Suppl):54S-64S

Department of Neurology, Mellen Center for Multiple Sclerosis Treatment and Research, the Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1051228404266269DOI Listing
July 2004

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

Expert Rev Neurother 2004 Jul;4(4):571-80

Department of Neurology, Center for Multiple Sclerosis Treatment and Research, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737175.4.4.571DOI Listing
July 2004

Multiple sclerosis: disease markers accelerate progress.

Lancet Neurol 2004 Jan;3(1):10

Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH, Cleveland, USA.

View Article

Download full-text PDF

Source
January 2004

Biologic impact of interferon antibodies, and complexities in assessing their clinical significance.

Authors:
Richard A Rudick

Neurology 2003 Nov;61(9 Suppl 5):S31-4

Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/01.wnl.0000092363.40248.0eDOI Listing
November 2003

Interferon gamma responses to myelin peptides in multiple sclerosis correlate with a new clinical measure of disease progression.

J Neuroimmunol 2003 Aug;141(1-2):132-40

Department of Neurosciences, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0165-5728(03)00221-2DOI Listing
August 2003

Interferon-beta 1a does not reduce expression of CCR5 and CXCR3 on circulating T cells.

J Neuroimmunol 2003 Aug;141(1-2):150-4

Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0165-5728(03)00247-9DOI Listing
August 2003

Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals.

J Neurovirol 2003 Jun;9(3):291-9

Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13550280390201001DOI Listing
June 2003

Flow cytometric analysis of chemokine receptor expression on cerebrospinal fluid leukocytes.

Methods 2003 Apr;29(4):319-25

Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
April 2003

Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis.

Mult Scler 2003 Feb;9(1):1-5

Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1191/1352458503ms888oaDOI Listing
February 2003

Sex differences in cytokine responses to myelin peptides in multiple sclerosis.

J Neuroimmunol 2002 Sep;130(1-2):211-23

Department of Neurosciences, Cleveland Clinic Foundation, 44195, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0165-5728(02)00224-2DOI Listing
September 2002